Literature DB >> 21724641

Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.

Shutong Xu1, Chen Zhong, Tianlong Zhang, Jianping Ding.   

Abstract

The SET- and myeloid-Nervy-DEAF-1 (MYND)-domain containing (Smyd) lysine methyltransferases 1-3 share relatively high sequence similarity but exhibit divergence in the substrate specificity. Here we report the crystal structure of the full-length human Smyd2 in complex with S-adenosyl-L-homocysteine (AdoHcy). Although the Smyd1-3 enzymes are similar in the overall structure, detailed comparisons demonstrate that they differ substantially in the potential substrate-binding site. The binding site of Smyd3 consists mainly of a deep and narrow pocket, while those of Smyd1 and Smyd2 consist of a comparable pocket and a long groove. In addition, Smyd2, which has lysine methyltransferase activity on histone H3-lysine 36, exhibits substantial differences in the wall of the substrate-binding pocket compared with those of Smyd1 and Smyd3 which have activity specifically on histone H3-lysine 4. The differences in the substrate-binding site might account for the observed divergence in the specificity and methylation state of the substrates. Further modeling study of Smyd2 in complex with a p53 peptide indicates that mono-methylation of p53-Lys(372) might result in steric conflict of the methyl group with the surrounding residues of Smyd2, providing a structural explanation for the inhibitory effect of the SET7/9-mediated mono-methylation of p53-Lys(372) on the Smyd2-mediated methylation of p53-Lys(370).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724641     DOI: 10.1093/jmcb/mjr015

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  13 in total

Review 1.  SET for life: biochemical activities and biological functions of SET domain-containing proteins.

Authors:  Hans-Martin Herz; Alexander Garruss; Ali Shilatifard
Journal:  Trends Biochem Sci       Date:  2013-10-20       Impact factor: 13.807

Review 2.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

3.  Function of the MYND Domain and C-Terminal Region in Regulating the Subcellular Localization and Catalytic Activity of the SMYD Family Lysine Methyltransferase Set5.

Authors:  Deepika Jaiswal; Rashi Turniansky; James J Moresco; Sabeen Ikram; Ganesh Ramaprasad; Assefa Akinwole; Julie Wolf; John R Yates; Erin M Green
Journal:  Mol Cell Biol       Date:  2020-01-03       Impact factor: 4.272

4.  The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.

Authors:  Shuman Gao; Zhiqiang Wang; Wencai Wang; Xueli Hu; Peilin Chen; Jiwen Li; Xinhua Feng; Jiemin Wong; James X Du
Journal:  J Biol Chem       Date:  2017-06-06       Impact factor: 5.157

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

6.  LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.

Authors:  Hannah Nguyen; Abdellah Allali-Hassani; Stephen Antonysamy; Shawn Chang; Lisa Hong Chen; Carmen Curtis; Spencer Emtage; Li Fan; Tarun Gheyi; Fengling Li; Shichong Liu; Joseph R Martin; David Mendel; Jonathan B Olsen; Laura Pelletier; Tatiana Shatseva; Song Wu; Feiyu Fred Zhang; Cheryl H Arrowsmith; Peter J Brown; Robert M Campbell; Benjamin A Garcia; Dalia Barsyte-Lovejoy; Mary Mader; Masoud Vedadi
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

Review 7.  Structure and function of SET and MYND domain-containing proteins.

Authors:  Nicholas Spellmon; Joshua Holcomb; Laura Trescott; Nualpun Sirinupong; Zhe Yang
Journal:  Int J Mol Sci       Date:  2015-01-08       Impact factor: 5.923

8.  Structural and functional analysis of the DEAF-1 and BS69 MYND domains.

Authors:  Fatiha Kateb; Helene Perrin; Konstantinos Tripsianes; Peijian Zou; Roberta Spadaccini; Matthew Bottomley; Titus M Franzmann; Johannes Buchner; Stephane Ansieau; Michael Sattler
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

Review 9.  Lysine-specific modifications of p53: a matter of life and death?

Authors:  Diana Marouco; Alexander V Garabadgiu; Gerry Melino; Nikolai A Barlev
Journal:  Oncotarget       Date:  2013-10

10.  SMYD2 glutathionylation contributes to degradation of sarcomeric proteins.

Authors:  Dhanushka N P Munkanatta Godage; Garrett C VanHecke; Kusal T G Samarasinghe; Han-Zhong Feng; Mark Hiske; Joshua Holcomb; Zhe Yang; Jian-Ping Jin; Charles S Chung; Young-Hoon Ahn
Journal:  Nat Commun       Date:  2018-10-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.